lyxumia
sanofi-aventis new zealand limited - lixisenatide 0.1 mg/ml - solution for injection - 0.1 mg/ml - active: lixisenatide 0.1 mg/ml excipient: glycerol hydrochloric acid metacresol methionine sodium acetate sodium hydroxide water for injection - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with metformin, metformin and sulphonylurea, basal insulin and metformin, basal insulin and sulphonylurea when these, together with diet and exercise, do not provide adequate glycaemic control (see sections clinical trials and precautions) (risk of hypoglycemia) for available data on the different combinations.
lantus solostar 100iuml solution for injection in a pre-filled pen
sanofi-aventis (malaysia) sdn. bhd. - insulin glargine -
apidra solostar 100 unitsml solution for injection in a pre-filled pen
sanofi-aventis (malaysia) sdn. bhd. - insulin glulisine -
nasacort aq nasal spray
sanofi-aventis (malaysia) sdn. bhd. - triamcinolone acetonide -
plaquenil tablets
sanofi-aventis (malaysia) sdn. bhd. - hydroxychloroquine sulphate -
aprovasc film coated tablet 150mg5mg
sanofi-aventis (malaysia) sdn. bhd. - irbesartan; amlodipine besilate -
aprovasc film coated tablet 300mg10mg
sanofi-aventis (malaysia) sdn. bhd. - irbesartan; amlodipine besilate -
aprovasc film coated tablet 150mg10mg
sanofi-aventis (malaysia) sdn. bhd. - irbesartan; amlodipine besilate -
aprovasc film coated tablet 300mg5mg
sanofi-aventis (malaysia) sdn. bhd. - amlodipine besilate; irbesartan -
soliqua solostar 100unitsml+33mcgml solution for injection in a pre-filled pen
sanofi-aventis (malaysia) sdn. bhd. - insulin glargine; lixisenatide -